Thalys(SH:603716) Zheng Quan Shi Bao Wang·2025-11-06 05:11Core Viewpoint - The article highlights that Seer Medical's strategic subsidiary, Huajiyuan Bio, has initiated a Phase I clinical trial for an innovative drug, HJY-ATRQβ-001 injection, which is a therapeutic vaccine for hypertension targeting the angiotensin II receptor type I. This marks a significant step as it has received ethical approval from the Ethics Committee of Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital [1]. Group 1 - Seer Medical's strategic investment in Huajiyuan Bio has led to the development of HJY-ATRQβ-001, an innovative therapeutic vaccine for hypertension [1]. - The Phase I clinical trial is being conducted in collaboration with Standeam (Beijing) Pharmaceutical as the CRO [1]. - The ethical approval from the relevant medical ethics committee signifies a crucial milestone in the drug's journey towards human clinical trials [1].